Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Zimmer Biomet Holdings Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Zimmer Biomet Holdings Inc trades at $89.63 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals.
| KARS | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $107.71 |
52-Week Low | $23.61 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with a bearish technical signal from moving averages and oscillators showing mixed signals. The stock faces headwinds from sector rotation away from traditional automakers toward efficient vehicles, as highlighted by recent news. Financial ratios are unavailable, limiting fundamental clarity, but the electric vehicle ETF context suggests exposure to evolving industry dynamics.
Outlook remains cautious due to technical weakness and sector pressures, though potential exists if EV adoption accelerates. Risks include competitive threats from Chinese automakers and regulatory uncertainty. Investors should await clearer financial data to assess valuation and growth prospects amid shifting market sentiment.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
